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AbstrACt
Introduction People with fibromyalgia (FM) suffer from 
symptoms such as widespread pain, non-refreshing 
sleep, fatigue and reduced quality of life. Effects of 
pharmacological treatment are questionable and non-
pharmacological treatments are recommended as first-line 
therapy. To date the majority of patients with FM in Norway 
are not offered any targeted treatment. The aim of this 
randomised controlled trial is to investigate the effects 
of a community-based multicomponent rehabilitation 
programme comprising an acceptance-based and 
mindfulness-based group intervention, the Vitality Training 
Programme (VTP), followed by tailored physical activity 
counselling.
Materials and methods General practitioners refer 
potential participants to a rheumatologist in specialist 
healthcare for diagnostic clarification and assessment of 
comorbidities. Inclusion criteria are widespread pain/FM 
≥3 months, age 20–50 and work participation (minimum 
part-time) within the last 2 years. The intervention group 
attends the VTP comprising 10 weekly 4 hour group 
sessions plus a booster session after 6 months. Thereafter, 
they receive 12 weeks of individually tailored physical 
exercise counselled by physiotherapists at community-
based Healthy Life Centers. The control group follows 
treatment as usual. The primary outcome is Patient Global 
Impression of Change. Secondary outcomes include self-
reported pain, fatigue and sleep quality, psychological 
distress, mindfulness, health-related quality of life, 
physical activity, work ability and exercise beliefs and 
habits. To achieve a power of 80% and allow for 10% 
dropout, 70 participants are needed in each arm. All 
analyses will be conducted on intention-to-treat bases and 
measured as differences between groups at 12 months 
follow-up.
Ethics and dissemination The study is approved and 
granted by the Norwegian South-Eastern Regional Health 
Authority (reference 2016015). Ethics approval was 
obtained from Regional Committee for Medical and Health 
Research Ethics (reference 2015/2447/REK sør-øst A). 
Results will be submitted to appropriate journals and 
presented in relevant conferences and social media.
trial registration ISRCTN 96836577.
IntroduCtIon
Fibromyalgia (FM) is a heterogeneous and 
still unexplained disease that poses major 
personal and societal challenges in terms 
of disease burden, non-fatal health loss and 
costs.1 2 It is one of the most common chronic 
pain conditions with an estimated preva-
lence of 2% worldwide.3 In Norway, it is esti-
mated that FM affects as much as 6% of the 
women and 3% of the men.4 The cardinal 
symptom of FM is widespread pain character-
ised by reduced pressure pain thresholds and 
hyperalgesia. In 2010, the American College 
of Rheumatology (ACR) introduced new 
diagnostic criteria that also included other 
somatic symptoms, such as non-refreshing 
sleep, fatigue, difficulties with memory and 
concentration, irritable bowel syndrome, 
headache and depression.5 The complexity 
of FM symptoms commonly reduces patients’ 
well-being and has an important influence 
on their quality of life.6 In Norway, FM is a 
common cause of sick leave, disability benefit 
strengths and limitations of this study
 ► The multicomponent rehabilitation programme con-
sists of modalities that have previously been found 
to be effective for people with rheumatic and mus-
culoskeletal diseases.
 ► Sustainability of effects will be measured at 1-year 
follow-up.
 ► The inclusion of patients from both rural and urban 
communities will enhance the generalisability of the 
results.
 ► It is not possible to examine the effectiveness of sin-
gle components of the programme.
 ► Some participants may experience the multicompo-
nent rehabilitation programme to be too comprehen-
sive and time-consuming.
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and extensive use of healthcare services.4 Although the 
FM diagnosis has become increasingly recognised during 
the last decades, there are still some physicians who ques-
tion its validity. Several patients experience disbelief, lack 
of understanding and stigmatisation from their general 
practitioners (GPs) as well as from the social security 
systems, colleagues and family.3 7 
Current treatments for FM are non-curative and the effi-
cacy of pharmacological treatment alone is questionable.8 
Recent updated evidence-based recommendations from 
the European League Against Rheumatism conclude 
that optimal management requires prompt diagnosis 
and thereafter a graduated follow-up.9 The initial 
management of FM should focus on patient education 
and non-pharmacological interventions, such as graded 
physical exercise and individually tailored psychological 
therapies for those with mood disorder or unhelpful 
coping strategies. The interventions may be combined in 
multicomponent rehabilitation programmes. Pharmaco-
therapy is only recommended for severe pain and sleep 
disturbances.9
In Norway, the main responsibility for management 
of FM is assigned to the primary healthcare services.10 
Some patients with FM are referred to physiotherapists 
and a few to rehabilitation in specialist care. However, to 
date, the majority of patients with FM are not offered any 
tailored treatment in the primary healthcare.
Mindfulness-based and acceptance-based training for 
patients with FM
It has been shown that women with FM may have 
maladaptive emotion regulation styles, such as difficulty 
in identifying and expressing feelings, which amplify pain 
and impede their adjustment to the disease. Moreover, 
women with FM commonly experience stressful and nega-
tive emotions related to depressive mood and anxiety.11 12 
In mindfulness-based and acceptance-based therapies, 
participants learn to accept their experiences of pain and 
stressful thoughts and emotions as part of human life that 
one can relate to rather than judging them as good or bad, 
positive or negative and thus fostering better emotional 
regulation.13 The core aspect of mindfulness is training in 
moment-to-moment awareness of internal experiences, 
such as thoughts, emotions and body sensations with an 
attitude of openness, curiosity, patience and acceptance.14 
Increased acceptance is believed to decrease the struggle 
to control what might not be controllable and seems to 
be associated with better treatment outcomes for pain 
patients.15 Systematic reviews on mindfulness training 
for patients with FM have shown evidence for small, but 
significant improvements of pain, depression, anxiety 
and quality of life.16 17
A Norwegian mindfulness-based and acceptance-based 
group intervention, the Vitality Training Programme 
(VTP) was developed for patients with chronic muscu-
loskeletal pain in the late 1990s.18 It was later adjusted 
for patients with inflammatory arthritis (IA).19 The 
VTP incorporates mindfulness training, values-based 
action and various creative methods. The main goals 
are to enhance participants’ awareness of their health 
promoting resources and to strengthen their inner 
authority and abilities to make conscious choices in line 
with their personal values. Two randomised controlled 
trials on the VTP, one in patients with chronic musculo-
skeletal pain, including FM, and one in patients with IA, 
showed reduced psychological distress, improved pain 
coping and mental well-being in the intervention groups 
compared with the control groups. The group with IA also 
showed decreased fatigue and increased self-efficacy. The 
effects were sustained or increased at 1-year follow-up.19 20 
However, a longitudinal pre-post-test study on the VTP 
in patients with IA and FM showed substantial improve-
ments in the IA group, but no changes in the FM group.21 
The reason for these differences remains unclear, but it 
may be related to the long symptoms duration without 
any targeted treatment in the patients with FM. On 
average, these patients had experienced pain symptoms 
more than 10 years before they were diagnosed with FM. 
Living with pain over many years without access to rele-
vant treatment might lead to development of maladaptive 
coping strategies that may be difficult to change. Hence, 
it was suggested that future studies should investigate 
effects of the VTP in patients with FM with more recent 
disease onset.21 22 The VTP is implemented in some rheu-
matology specialist departments and in specialist rehabil-
itation, but to date there is no systematic implementation 
and evaluation in primary healthcare.
Physical exercise for patients with FM
Physical exercise has been defined as physical activity that 
is planned, structured and repetitive with the goal to main-
tain or improve physical fitness, that is, cardiorespiratory 
endurance, muscular strength and flexibility.23 Studies 
have demonstrated that compared with healthy women 
people with FM are less physically active.24 Two systematic 
reviews on physical exercise in patients with FM found 
evidence that aerobic exercise reduces pain, fatigue and 
depressed mood and improves health-related quality of 
life and physical fitness.25 26 The amount and intensity of 
initial aerobic exercises should be adapted to the indi-
vidual level of physical fitness and patients should start at 
a level just below their capacity and gradually increase the 
duration and intensity.25 Studies have demonstrated that 
appropriately progressed muscle strengthening activities 
is safe and effective for individuals with FM and should 
be considered as part of a multicomponent rehabilitation 
programme.26
Since 2004, Healthy Life Centres (HLCs) have been 
established in most Norwegian municipalities.27 The 
HLCs are based on a salutogenic framework aiming 
at strengthening peoples’ capacities to use their own 
health resources and make health-friendly choices. 
They provide low-threshold easily accessible activities 
and interventions targeted at supporting behavioural 
changes and management of lifestyle issues, such 
as indoor and outdoor physical activity, healthy diet 
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courses, smoking cessation and short mental health 
interventions. The physical activity interventions 
include aerobic and strengthening exercises usually 
twice a week for a 12-week period. Some HLCs also offer 
yoga and mindfulness exercises. Health professionals 
working at HLCs are mainly physiotherapists and nutri-
tionists. All are educated in Motivational interviewing 
(MI), which is both a treatment philosophy and a set 
of methods employed to help people increase intrinsic 
motivation by exploring and resolving ambivalence 
about behavioural change. MI has demonstrated effec-
tiveness for clients regardless of problem severity, age 
and gender.28 One of the main groups that use HLCs 
is people with chronic pain condition, including FM. 
However, many patients with FM are reluctant to partic-
ipate in the general exercises because they are afraid of 
increasing their pain. For patients with FM, it seems to 
be important that the exercise programmes are individ-
ually tailored and that the graded approach is followed.
Aim and research questions
The overall aim of this trial is to evaluate the effects of a 
multicomponent rehabilitation programme for patients 
with newly diagnosed FM delivered in primary healthcare.
The primary objective is to study the hypothesis that 
patients with newly diagnosed FM who participate in 
a community-based multicomponent rehabilitation 
programme will improve their self-perceived health 
compared with patients who follow their ‘treatment as 
usual’. The rehabilitation programme comprises the VTP 
plus 12 weeks physical activity counselling at a HCL.
More specifically, the study will investigate the following 
research questions:
1. Does a community-based multicomponent rehabilita-
tion programme relieve symptoms burden of patients 
with newly diagnosed FM in terms of reduced pain, 
fatigue, sleep disturbances and psychological distress?
2. Does a community-based multicomponent rehabilita-
tion programme increase physical activity of patients 
with FM?
3. Does a community-based multicomponent rehabilita-
tion programme increase work ability of patients with 
newly diagnosed FM?
trial development and design
A project group including a patient representative, two 
GPs, a representative for community rehabilitation service, 
a rheumatologist and health professionals educated as 
VTP facilitators have been involved in the project devel-
opment and will be consulted throughout the trial. The 
study is a pragmatic parallel randomised controlled trial 
with two arms (ISRCTN 96836577). The multicomponent 
rehabilitation programme is a complex intervention with 
several interacting components, such as a group inter-
vention with several interactive methods plus individually 
tailored physical exercise counselling. The project group 
has followed the new Medical Research Council guidance 
for Developing and evaluating complex interventions.29 
The protocol has been developed in line with the SPIRIT 
guidelines (Standard Protocol Items: Recommendations 
for Interventional Trials)30 (online supplementary file 1).
MEthods
study setting and recruitment of participants
The trial is a collaboration between the rheumatology 
specialist department at Diakonhjemmet Hospital in 
Oslo, two municipal districts in the city of Oslo and six 
rural municipalities in geographical proximity to Oslo. 
GPs and physiotherapists in the eight municipalities 
will identify potential patients and refer the patients to 
a rheumatologist at Diakonhjemmet Hospital for diag-
nosis clarification and assessment of comorbidities. To 
enhance recruitment, the project coordinator (TH) and 
the project leader (HAZ) have visited all GP offices in the 
eight municipalities and written information is sent by 
email and per post. Moreover, flyers have been distrib-
uted to offices and waiting areas for potential patients 
informing them to contact their GP if they are in the 
target group for the project. Information is also shared in 
relevant website and social media.
Patients will be examined and screened for eligibility by 
the rheumatologist. All eligible patients will be offered a 
3-hour FM group education programme by a rheumatolo-
gist and a nurse, aimed at providing basic understanding 
about FM, pain mechanisms, psychological factors, phys-
ical activity and coping strategies. Short mindfulness 
and yoga exercises will be introduced. This programme 
is currently part of standard care for patients with FM 
at Diakonhjemmet Hospital. Additionally, the project 
coordinator will inform about the VTP and present the 
logistics of the study. The patients have the opportu-
nity to ask questions before they consent to participate. 
The programme will be arranged regularly throughout 
the recruitment period until the target sample size is 
obtained.
The multicomponent rehabilitation programme will be 
conducted in the municipalities. HAZ and TH will orga-
nise the VTP at central places in Oslo and the rural munic-
ipalities. The physical exercise will take place at a HCL in 
the participants’ home communities. If the community 
has not yet established a HCL, the participants will be 
referred to a HCL in a nearby community. Participants 
will follow the HLC’s ordinary 12-week physical activity 
counselling and exercise programme (figure 1).
Eligibility criteria
Patients are eligible for inclusion if they are diagnosed 
with FM according to the ACR 2010 criteria for FM5 and 
aged between 20 and 50 years. Patients will be excluded 
if they have a comorbid inflammatory rheumatic disease, 
have been out of work for more than 2 years due to their 
pain condition, have a serious psychiatric disorder, have 
another disease that does not allow physical exercise or 
are unable to understand and write Norwegian.
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Interventions
The Vitality Training Programme
The VTP comprises 10 weekly 4-hour group sessions plus 
a booster session after about 6 months. Each group have 
between 8 and 12 participants. Every session addresses 
a specific topic related to living with long-lasting health 
challenges: If my body could talk/Who am I?/Values—
what is important to me?/What do I need?/Strengths 
and limitations/Bad conscience/Anger/Joy/Resources, 
potentials and choices/The way ahead18 19 (online supple-
mentary file 2). The participants are invited to explore 
these topics by using various creative methods, such as 
guided imagery, music, drawing, poetry and metaphors. 
The purpose is to provide opportunities for personal 
discoveries by intentionally attending to emotional, cogni-
tive and bodily experiences. Participants are also invited 
to write logs from all exercises and to share their expe-
riences and discoveries with other group participants. 
Figure 1 Study flowchart. FM, fibromyalgia.
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Moreover, participants are invited to attend to mindful-
ness meditation exercises, that is, body scan, sitting and 
walking meditation and breathing exercises. They are 
provided with guided mindfulness audio files and are 
encouraged to practice these exercises in everyday life 
and to train awareness in daily activities. Moreover, the 
VTP includes gentle yoga exercises that can help partic-
ipants explore their physical boundaries and overcome 
barriers to movement. Throughout the programme, 
participants learn how to balance rest with activity, iden-
tify activities that are important and healthful to them 
and how to overcome barriers to prioritise these activities 
(values-based action).
All groups have two facilitators who are certified through 
a 1 year university training programme (30 crd) at VID 
Specialized University in Oslo. They follow a manual with 
a thorough programme description.18 Adherence to the 
intervention, that is, attendance in group sessions will be 
recorded by the group facilitators. The participants need 
to attend at least 50% of the sessions to expect effect. They 
will also be asked to report any adverse events (online 
supplementary file 3).
Individual physical activity counselling and tailored physical 
exercise
After completing the VTP, participants will be offered 
individual physical activity counselling by a physiother-
apist at the HLCs. Interviews based on MI with focus 
on individual planning and goalsetting on activity and 
participation level will be conducted before start-up, 
after 6 weeks and at the end of week 12. The goals will 
be defined by the participant in collaboration with a 
physiotherapist. A common goal may be to reduce pain. 
An activity plan may be to perform strengthening and 
aerobic exercises, for example, cycling or Nordic walking 
three times a week. Another aim is to learn the balance 
between activity and rest and find the right dosage of 
the exercises. The purpose of the counselling is to help 
participants identify and overcome barriers to physical 
activity, to find exercises that can be easily continued in 
their everyday life and gradually increase their levels of 
physical activity. The physical exercise will be adapted 
to each participant’s individual level of physical fitness. 
The physiotherapists will record adherence to the HLC 
intervention and any adverse events during the 12-week 
period.
Control group
Patients randomised to the control group will not receive 
any intervention other than the 3-hour FM education. 
They will follow their ‘treatment as usual’ in primary care, 
that is, GP consultations and any physical activity they may 
choose. At the FM course, all participants are told that 
they can follow any new information as they would like. 
This means that control group participants may initiate 
life-style changes on their own initiative. There are no 
restrictions on participation in physical activities during 
the trial. The control group will be offered the VTP after 
completion of the last data collection, that is, 1 year after 
inclusion.
Outcomes
Outcome measures are selected according to the core 
set of domains for FM defined by the Outcome Measures 
in Rheumatology Clinical Trials (OMERACT).31 32 All 
outcomes are self-reported.
Primary outcome will be Patient Global Impression 
of Change (PGIC) that evaluates overall health status 
as perceived by the patient in a 7-point single-item scale 
ranging from 1 (‘I feel very much worse’) through 4 (‘no 
change’) to 7 (‘I feel very much better’) 1 year after inclu-
sion.33 Scores of 6 and 7 are considered clinically relevant 
improvement.34 This measure has previously been used in 
FM trials.33 35 36
Secondary outcomes related to the specific research 
questions will be collected at baseline, 3 and 12 months. 
The outcomes include:
 ► Pain, fatigue and sleep quality assessed by Numerical 
Rating Scales scored from 0 to 10 (10 is intolerable 
pain/fatigue/very bad sleep quality).
 ► Psychological distress assessed by the General Health 
Questionnaire-12 (GHQ-12), a widely used screening 
instrument measuring aspects of psychological health 
during the last 2 weeks.37 The GHQ-12 comprises 
six positively phrased items, indicating psycholog-
ical health, and six negatively phrased items, indi-
cating psychological distress. The respondents are 
requested to compare their current status with what 
they consider as their ‘normal’ condition on a four-
point Likert scale, scored from 0 (less than usual) to 
3 (much more than usual). This gives a possible sum 
score between 0 (no distress at all) and 36 (much 
more distress than usual).37 38
 ► Mindfulness assessed by The Five Factor Mindfulness 
Questionnaire (FFMQ) that measures a general 
tendency to be mindful in daily life. FFMQ comprises 
39 items rated on a five-point Likert scale from 
1 (never or very rarely true) to 5 (always or almost 
always true).39 40
 ► Health-related quality of life assessed by the EuroQol 
(EQ-5D-5 L) comprising five dimensions of mobility, 
self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension is scored on five 
levels: no problems, slight problems, moderate prob-
lems, severe problems and extreme problems. Addi-
tionally, ‘perceived health today’ is scored from 0 (as 
bad as it could be) to 100 (as good as it could be).41 
The instrument has been validated in similar popula-
tions42 and in Norwegian context.43
 ► Physical activity assessed by three questions addressing 
the average number of times exercising each week 
and the average intensity and average duration each 
week.44
 ► Motivation and barriers for physical activity assessed by 
the Exercise Beliefs and Exercise Habits question-
naire comprising 20 items that reflect beliefs about 
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one’s ability to exercise, barriers to exercise, benefits 
of exercise and impact of exercise on muscular pain. 
Items are scored on a five-point Likert scale, ranging 
from strongly agree to strongly disagree.45
 ► Work ability assessed by the Work Productivity and 
Activity Impairment General Health V2.1 (WPAI:GH) 
that comprises six questions to determine employ-
ment status, hours missed from work because of health 
problems or other reasons, hours actually worked, 
the degree to which health problems affected work 
productivity while at work and activities outside of 
work.46 WPAI outcomes are expressed as impairment 
percentages with higher numbers indicating greater 
impairment and less productivity.
Moreover, the data collection includes self-reported 
healthcare consumption, that is, visits to GP, rheuma-
tologist, physiotherapist and other healthcare profes-
sionals, use of medication and alternative treatments. 
Self-reported adverse events will be collected electroni-
cally at 12 months. The respondents report if they have 
or have not experienced any adverse events. If relevant, 
the respondents report whether they perceived the 
events caused by the VTP or the HLC intervention with 
the possibility to elaborate (online supplementary file 
3).
sample size
Sample size calculation is based on the primary outcome 
assuming that 10% in the control group will report that 
they ‘feel much better’ or ‘very much better’ after 12 
months35 and that at least a 20% absolute difference in 
improvement rate between the groups can be considered 
as a minimal clinically relevant difference. We anticipate 
10% losses to follow-up and will need 70 participants in 
each group to have at least 80% power of detecting differ-
ences with 5% alpha level.
randomisation and allocation concealment
A statistician has generated an electronic randomisation 
list based on blocks of 20–24 for each geographical area to 
ensure approximately equal sample sixes. Participants will 
be given consecutive numbers. A secretary not involved in 
the data collection or the intervention will allocate each 
participant to the corresponding number on the rando-
misation list and inform the patients about group alloca-
tion by telephone and written letter. Due to the nature of 
the implementation strategy, it is not possible to blind the 
patients or the health professionals. The project leader 
and the research coordinator who are responsible for 
the data collection and data analyses will not be aware of 
group allocation.
data collection
Participant flow is shown in figure 1. Data will be collected 
electronically by a solution delivered by Infopad (http://
www. infopad. no) before randomisation (baseline), after 
the VTP (3 months) and at 12 months from baseline. This 
electronic solution is risk evaluated and follows the Code 
of Conduct for information security in the healthcare and 
care services.47
Participants will be registered in the electronic system 
by the project coordinator. Participants receive an email 
with a unique link to the questionnaire at each assessment 
point and can respond to the questionnaire on their indi-
vidual electronic device (computer, mobile phone or 
tablet). Participants who do not possess an electronic 
device will receive a paper version of the questionnaire.
statistical analysis
The treatment effects will be analysed on an intention-
to-treat basis with all randomised participants retaining 
their original allocated group and measured as differ-
ences between groups at 12 months. Analyses of covari-
ance will be used for continuous outcomes with baseline 
values as covariates. Logistic regression analyses for 
dichotomous outcomes. The level of significance will be 
set to p≤0.05 and the confidence level to 95%. We will use 
the STATA V.14.0 (Texas, USA) to analyse the data.
Ethical approval
Study design, information strategy, written consent 
formula and data security are approved by the Regional 
Committee for Medical and Health Research Ethics 
(2015/2447/REK sør-øst A). The trial will be carried out 
in accordance with the Helsinki Declaration. Participants 
will receive written and oral information about the study 
processes and interventions before they sign a written 
declaration of voluntary participation. They have the 
right to withdraw from the study at any time without any 
explanation.
All included participants will receive a consultation 
with a rheumatologist and a brief patient education inter-
vention that either corresponds to or is better than their 
currently provided care. Participants who are randomised 
to the multicomponent rehabilitation programme will 
receive a potentially more effective intervention. Control 
group participants will receive the current standard of 
care that is delivered in their respective community. Thus, 
no participants will receive an intervention that is below 
standard treatment. Any potential adverse events will 
be registered throughout the trial period. All personal 
information about potential and enrolled patients as 
well as patient consent forms will be securely stored in 
paper formats in a locked closet in a locked room. Elec-
tronic data will be stored in a password protected solution 
(http://www. infopad. no) during the study and for 5 years 
after completion. The project leader (HAZ) will regu-
larly review the data collection process and ensure that 
the data are collected, stored and handled in accordance 
with the current guidelines. The data are only available to 
the project leader (HAZ), the project coordinator (TH) 
and the project secretary.
Patient and public involvement
The VTP was developed in the 1990s in close collabo-
ration with people with chronic musculoskeletal pain.18 
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The burden of the intervention has been assessed in 
the two previous randomised controlled trials.18 22 The 
present project emerged from informal conversations 
between the project manager (KBH), the project leader 
(HAZ) and the leader of the FM group in the Norwegian 
Rheumatism Association (EB). Further development of 
the project, such as study design, research questions and 
recruitment of patients has been thoroughly discussed 
with representatives for the Patient Advisory Board at the 
rheumatology department at Diakonhjemmet Hospital. 
The electronic questionnaire has been tested and 
amended by user representatives.
In addition to publishing in international peer-reviewed 
journals, the results of the study will be disseminated 
through various information channels to the project 
group members and the public, including websites, social 
media, national and international networks, conferences 
and congresses. Moreover, the results will be published 
in a yearly special issue of the journal of the Norwegian 
Rheumatism Association that focuses on resent research 
and communicated to patients in relevant meetings 
arranged by this association.
dIsCussIon
FM is a complex chronic condition with extensive use of 
healthcare services and important impact on patients’ 
quality of life. Current pharmacological treatments for 
patients with FM are not curative and initial manage-
ment should be non-pharmacological.9 Patients with FM 
should be treated in primary healthcare, but to date the 
majority of patients with FM are not offered any targeted 
interventions. This paper describes the rationale and 
design of an RCT investigating the effects of a multicom-
ponent community-based rehabilitation programme for 
patients with FM. The rehabilitation programme will 
fill a gap in the management of people with FM and if 
found effective, can be recommended as a rehabilitation 
model for people with FM in primary healthcare. We aim 
at reaching patients at an early stage of their disease to 
prevent further development of disability and therefore 
we will include only patients of 50 years and below and 
patients who have not been out of work for more than 
2 years due to their pain condition. The design of the 
multicomponent rehabilitation programme is based on 
updated international recommendations for manage-
ment of FM, including a group-based coping interven-
tion to strengthen patients’ health promoting resources 
(the VTP) and graded physical exercise.9 The rationale 
for offering patients the VTP before the physical activity 
counselling is that many patients may have previous 
stressful life experiences and emotional burdens that may 
be a barrier to lifestyle change.48 Throughout the VTP, 
the participants may acquire alternative coping strategies 
and more constructive ways to deal with stress, which may 
facilitate their participation in physical exercise. The indi-
vidual physical activity counselling will follow the current 
practice at the HLCs and thus ensure the feasibility of 
the intervention and strengthen the external validity of 
the study. The inclusion of patients from both rural and 
urban communities will also enhance the generalisability 
of the results.
Some participants may experience the multicompo-
nent rehabilitation programme to be too comprehen-
sive and recruiting sufficient number of patients may be 
a challenge. GPs in the respective municipalities will be 
approached with information about the project before 
and during the study period. Moreover, potential partic-
ipants will be given extensive information about the 
programme before they consent to participate and again 
before they start the VTP in order to enhance adherence. 
Previous research shows that behavioural change takes 
time and that interventions that include multiple strate-
gies are more successful.49 Many patients with FM express 
frustration about the lack of treatment possibilities and 
have felt neglected by the healthcare system.50 They are 
likely to be motivated to receive any treatment that can 
improve their condition. Moreover, the Norwegian social 
security system can provide ‘sick-leave for single treat-
ment days’ to facilitate participation during work time.
The effect of the intervention will be measured in 
accordance with its aims and content. The validity of the 
primary outcome measure, PGIC, has been assessed in a 
prospective observational cohort study in patients with 
FM and was found to be a clinically relevant measure to 
assess perceived impact of disease management.33 The 
secondary outcomes are based on a recommended core 
set from OMERACT32 and thus enable comparison with 
results from other studies.
The study has been developed in close collaboration 
with a project group comprising a patient partner, a 
rheumatologist, two GPs and a health professional repre-
senting rehabilitation service in one of the communities. 
If the intervention is proven effective, this group will 
contribute to disseminating and implementing the results 
in clinical practice.
trial status
Enrolment for the trial began in November 2016 and 
recruitment is still in progress. Data collection will 
continue until the target sample size is reached, approxi-
mately December 2018.
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